Drug benefits have responded to the rise in drug costs by increasing patient cost sharing. However, many now realize that increasing cost sharing for high-value preventive-care drugs can be detrimental in terms of reducing patient drug adherence and causing increased inpatient and outpatient...

The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical...